Difference between revisions of "Duvelisib (Copiktra)"
m (→References) |
|||
Line 12: | Line 12: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | *9/24/2018: Regular approval | + | *9/24/2018: Regular approval for adult patients with relapsed or refractory [[Chronic lymphocytic leukemia|chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)]] after at least two prior therapies. ''(Based on DUO)'' |
− | *9/24/2018: Accelerated approval | + | *9/24/2018: Accelerated approval for adult patients with relapsed or refractory [[Follicular lymphoma|follicular lymphoma (FL)]] after at least two prior systemic therapies. ''(Based on DYNAMO)'' |
==Also known as== | ==Also known as== |
Revision as of 11:58, 26 May 2021
Mechanism of action
From NCI Drug Dictionary: An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, PI3K delta/gamma inhibitor IPI 145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.[1][2][3]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 9/24/2018: Regular approval for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. (Based on DUO)
- 9/24/2018: Accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. (Based on DYNAMO)
Also known as
- Code name: IPI-145
- Brand name: Copiktra